PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that Heiner Dreismann, Ph.D., former president and chief executive officer of Roche Molecular Systems, Inc., has joined its board of directors. Effective immediately, his addition brings the total number of board members to seven.
Dr. Dreismann possesses more than 27 years of global diagnostics experience in various positions at Roche Diagnostics and later Roche Molecular Systems (RMS), a business unit of Roche Diagnostics. In his last role at RMS, Dreismann oversaw the doubling of the molecular in vitro diagnostics business to over $1 billion and had overall responsibilities for business, corporate and R&D functions, as well as the respective staff.
"Dr. Dreismann has been on the cutting edge of the molecular diagnostics industry for his entire career, and his experience will be invaluable as a member of PDI's board of directors," said Jerry Belle, Chairman of the Board, PDI, Inc. "Dr. Dreismann's extensive industry and technical knowledge, business acumen and ability to effect change perfectly aligns with our long term vision and strategy for PDI."
Dr. Dreismann also serves on the boards of directors of several other public and privately held companies, including GeneNews, Stratos Genomics, Magellan Diagnostics, Singulex, Celula, Inc. and Myriad Genetics, among others."I am honored at this election to PDI's board and look forward to contributing my insight and perspectives as a member," said Dreismann. "The company is truly evolving as an innovative healthcare company and as a commercially-oriented molecular diagnostics company. I eagerly anticipate playing a role in helping to further its progress."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts